Skip to content
DataLookout
Menu

NCT01704716

High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Sep 30, 2021 to Jan 30, 2025 Show 9 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Trial status changed: Unknown → Completed
    • Trial sites reduced: 126 → 122 locations
    • Enrollment target: estimated 3300 to confirmed 3569
    • Start date: Feb 2002 to Feb 1, 2002
    • Interventions: Aldesleukin (Drug), Busulfan (Drug), Carboplatin (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Doxorubicin (Drug), Etoposide (Drug)… to Aldesleukin (Drug), Busulfan (Drug), Carboplatin (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Doxorubicin (Drug), Etoposide (Drug)…
    • Publications: details revised at 10 of 10 entries
    • Study title revised
    • Study description expanded, about 2 words
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary completion date: Nov 2019 to Sep 30, 2021
    • Study completion date: Sep 2024 to Sep 2026
    • Publications: 6 to 10
    v6
  4. Notable Primary completion date: Sep 2017 to Nov 2019v5 Show 7 more changesShow less
    • Primary endpoints revised (4)
    • Enrollment target: 2700 to 3300
    • Study sites: 116 to 126
    • Study completion date: Sep 2017 to Sep 2024
    • Study description expanded, about 232 words
    • Publications: details revised at 1 of 6 entries
    • Study title revised
  5. Notable Primary and study completion dates: Sep 2016 to Sep 2017
    • Study sites: 115 to 116
    v4
  6. Notable Primary and study completion dates: Dec 2014 to Sep 2016v2 Show 6 more changesShow less
    • Primary endpoints revised (4)
    • Enrollment target: 2000 to 2700
    • Interventions: Aldesleukin (Drug), Busulfan i.v. (Drug), Carboplatin (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Doxorubicin (Drug), Etoposide… to Aldesleukin (Drug), Busulfan (Drug), Carboplatin (Drug), Cisplatin (Drug), Cyclophosphamide (Drug), Doxorubicin (Drug), Etoposide (Drug)…
    • Study description expanded, about 220 words
    • Study arms: 8 to 10
    • Study title shortened, about 1 word
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Event Free Survival (R1: MAT therapy)
Timeframe: Up to three years
Event Free Survival (immunotherapy)
Timeframe: Up to three years
Complete metastatic response (R3: Induction therapy)
Timeframe: Up to 95 days
Event free survival (R3: Induction therapy)
Timeframe: Up to three years

Arms and interventions

R0: COJEC plus G-CSFExperimental

Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.

R0: COJECActive comparator

Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF

R1: BuMel MATActive comparator

The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan. In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)

R1: CEM MATExperimental

The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course

R2: ch14.18/CHOActive comparator

ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses

R2: ch14.18/CHO plus AldesleukinExperimental

Patients randomised to receive ch14.18/CHO plus Aldesleukin

R3: COJEC InductionActive comparator

Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days: Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide

R3: Modified N7Experimental

The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).

R4: cnt inf ch14.18/CHOActive comparator

ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO

R4: cnt inf ch14.18/CHO plus AldesleukinExperimental

ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO. In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion

Drugs: Vincristine, Aldesleukin, ch14.18/CHO, Carboplatin, Etoposide, Cisplatin, Cyclophosphamide, Doxorubicin, G-CSF, Busulfan, Melphalan

Sites

122 sites in 20 countries

Italy 22, United Kingdom 21, Spain 15, France 13, Poland 10, Belgium 6, Austria 5, Hungary 5, Denmark 4, Greece 4, Israel 3, Norway 3, Australia 2, Sweden 2, Switzerland 2, Czechia 1, Ireland 1, Portugal 1, Slovakia 1, Slovenia 1